Cancer is a severe disease that substantially jeopardizes global health. Although
considerable efforts have been made to discover effective anti-cancer therapeutics, the …

Simple Summary This review provides an in depth analysis of the role of bromodomain-
containing proteins in cancer development. As readers of acetylated lysine on nucleosomal …

Multiple myeloma (MM) is a hematological malignancy that exhibits aberrantly high levels of
proteasome activity. While treatment with the proteasome inhibitor bortezomib substantially …

Multiple myeloma (MM) is a genetically heterogeneous disease that includes a subgroup of
10–15% of patients facing dismal survival despite the most intensive treatment. Despite …

Standard risk stratification (sRisk) guides clinical management in monoclonal gammopathy
of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and multiple …

Simple Summary In the last decade, proteasome inhibitors (PIs) have become a standard for
the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs …

Purpose: Cyclin D1 has been identified as a proto-oncogene associated with the
uncontrolled proliferation of tumor cells. This systematic review and meta-analysis aims to …

Introduction Multiple myeloma (MM) is a heterogeneous disease where cancer-driver
mutations and aberrant signaling may lead to disease progression and drug resistance …

Simple Summary Personalized treatment for patients with relapsed or refractory multiple
myeloma (r/r MM) remains an ongoing challenge, and there are no anti-myeloma therapies …

The aim of this study was to identify novel plasma metabolic signatures with possible
relevance during multiple myeloma (MM) development and progression. A biochemical …